Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Experimental study of adoptive immunotherapy using CD3AK cells].

Ying-xun Sun1, Shao-hui Cheng, Ming Yu

  • 1Institute of Basic Medicine, Academy of Military Medical Sciences, Beijing 100850, China. sunyx@amms.ac.cn

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi = Chinese Journal of Cellular and Molecular Immunology
|March 16, 2005
PubMed
Summary

A novel monoclonal antibody (mAb) against CD3, named yCD3, effectively activates T cells. This activation significantly enhances the tumor-suppressive activity of CD3AK cells in both laboratory settings and living organisms, paving the way for new cancer immunotherapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to Ultrasonic-Assisted Ionic Liquid Extraction of Two Biflavonoids from <i>Selaginella tamariscina</i>.

ACS omega·2021
Same author

Muscle regeneration controlled by a designated DNA dioxygenase.

Cell death & disease·2021
Same author

Nomograms to Predict Overall and Cancer-Specific Survival in Gastric Signet-Ring Cell Carcinoma.

The Journal of surgical research·2021
Same author

Spleen Stiffness Performance in the Noninvasive Assessment of Gastroesophageal Varices after Transjugular Intrahepatic Portosystemic Shunts.

BioMed research international·2021
Same author

Can Circulating Cell-Free DNA or Circulating Tumor DNA Be a Promising Marker in Ovarian Cancer?

Journal of oncology·2021
Same author

Bioequivalence of a Generic Nateglinide Formulation in Healthy Chinese Volunteers under Fasting and Fed Conditions: A Randomized, Open-Label, Double-Cycle, Double-Crossover Study.

Pharmacology·2021

Area of Science:

  • Immunology
  • Cell Biology
  • Oncology

Background:

  • Monoclonal antibodies (mAbs) targeting cell surface molecules are crucial in cancer therapy.
  • The CD3 molecule on T cells is a key target for immune modulation.
  • Understanding the activity of engineered T cells is vital for developing effective immunotherapies.

Purpose of the Study:

  • To characterize the immunological properties and biological activity of a novel anti-CD3 monoclonal antibody (yCD3).
  • To evaluate the in vitro and in vivo tumor-suppressive potential of CD3-activated killer (CD3AK) cells.
  • To establish a foundation for adoptive immunotherapy in clinical settings.

Main Methods:

  • Flow cytometry (FCM) for specificity and phenotype analysis of yCD3 and CD3AK cells.

Related Experiment Videos

  • 3H-TdR assay to measure lymphocyte proliferation upon yCD3 activation.
  • Lactate dehydrogenase (LDH) assay for in vitro cytotoxic activity assessment.
  • In vivo studies using tumor-bearing mice to evaluate anti-tumor effects.

    • Main Results:

    • yCD3 specifically binds to T cells and competitively inhibits standard anti-CD3 antibody binding.
    • yCD3 stimulates peripheral blood lymphocyte proliferation, further enhanced by IL-2 or anti-CD28.
    • Activated CD3AK cells showed increased CD3+, CD8+, CD25+ populations and elevated IL-2 and IFN-gamma production.
    • CD3AK cells demonstrated significant in vitro cytotoxicity (57.54% target cell killing) and in vivo tumor inhibition (33.17%) and lung metastasis reduction (39.70%).
    • Combined treatment with CD3AK and LAK cells showed enhanced efficacy.

    Conclusions:

    • The anti-CD3 mAb yCD3 effectively activates T cells.
    • yCD3 significantly induces tumor-suppressive activity of CD3AK cells in vitro and in vivo.
    • These findings support the potential of yCD3-activated CD3AK cells for adoptive cancer immunotherapy.